ALK and adenocarcinoma: Such mutations usually involve fusions of the ALK gene with other genes, most commonly EML4-ALK fusions, and these mutations are predominantly found in non-smokers, younger patients, and patients with adenocarcinoma subtypes, with an incidence of 3%-5%.